Sickle Cell Disease Clinical Trials in New York, New York

10 studies are recruiting for sickle cell disease in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

   Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking i…

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Columbia University Medical Center_New York_0, New York, New York

   Locations

   107 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06609226 on ClinicalTrials.gov

2. A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

   This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mount Sinai Hospital, New York, New York

   Locations

   9 in total

   Run by

   Disc Medicine, Inc

   See if you can join NCT07187973 on ClinicalTrials.gov

3. A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

   The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Locations

   80 in total

   Run by

   Pfizer

   See if you can join NCT05431088 on ClinicalTrials.gov

4. ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

   In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond…

   Stage

   Not phased

   Ages

   Any age

   Site

   Weill Cornell Medical College - New York Presbyterian Hospital, New York, New York

   Locations

   76 in total

   Run by

   American Thrombosis and Hemostasis Network

   See if you can join NCT04398628 on ClinicalTrials.gov

5. Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

   This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynam…

   Stage

   Phase 1

   Ages

   12 to 50

   Site

   Columbia University Irving Medical Center, New York, New York

   Locations

   6 in total

   Run by

   Kamau Therapeutics

   See if you can join NCT04819841 on ClinicalTrials.gov

6. Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

   This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.

   Stage

   Phase 3

   Ages

   12 to 35

   Site

   New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New York, New York

   Locations

   6 in total

   Run by

   Vertex Pharmaceuticals Incorporated

   See if you can join NCT05477563 on ClinicalTrials.gov

7. Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

   This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate …

   Stage

   Phase 2

   Ages

   2 to 25

   Site

   Columbia University, New York, New York

   Locations

   7 in total

   Run by

   Robert Nickel

   See if you can join NCT03587272 on ClinicalTrials.gov

8. A Long-term Follow-up Study in Patients Who Received BEAM-101

   This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed fo…

   Stage

   Not phased

   Ages

   14 to 37

   Site

   Columbia University Irving Medical Center, New York, New York

   Locations

   17 in total

   Run by

   Beam Therapeutics Inc.

   See if you can join NCT07373639 on ClinicalTrials.gov

9. Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain

   The study, known as the Peer suppoRt for adolescents and Emerging adults with Sickle cell pain: promoting ENgagement in Cognitive behavioral thErapy (PRESENCE), aims to determine the effectiveness of digital CBT in reducing pain, opioid use, and healthcare utilization among AYAs with SCD. It also s…

   Stage

   Not phased

   Ages

   16 to 30

   Site

   Weil Cornell Medical College, New York, New York

   Locations

   14 in total

   Run by

   University of Pittsburgh

   See if you can join NCT06374238 on ClinicalTrials.gov

10. Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain

    A randomized, double blind, study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mount Sinai Hospital, New York, New York

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT05519111 on ClinicalTrials.gov